CYTENA
Julian Riba has a diverse work experience. Julian started as a Research Scholar at the Palo Alto Research Center (PARC) in 2011. After that, they joined the IMTEK, University of Freiburg in 2014 as a PhD Student & Project Leader. In 2016, they transitioned to CYTENA and worked as an Application Scientist & Engineer until 2018. Then, they became the Chief Scientific Officer (CSO) at CYTENA and held this role until 2021. Currently, Julian Riba is the CEO of CYTENA starting from June 2021.
Julian Riba has a solid education history. Julian began their academic journey at the University of Alberta in 2010 as a Visiting Graduate Student, focusing on Mechanical Engineering. After completing this program, they enrolled at the Technical University of Munich in 2007, where they obtained their degree in Mechanical Engineering, specifically a Dipl.-Ing. degree, in 2013. Later on, Julian pursued further education at the University of Freiburg from 2014 to 2019, successfully achieving a Doktor (Ph.D.) degree. Although the field of study is not provided for their Ph.D., their previous degrees suggest a consistent background in Mechanical Engineering.
CYTENA
cytena GmbH has developed a device called cy-Clone to separate single cells. Single cells are required for the development of state-of-the-art drugs, so-called biologicals as well as for the genetic analysis of single cells for cancer and stem cell research. The cy-Clone is supported by an automated imaging process to encapsulate cells indroplets, which are delivered to any type of substrate. Thanks to this particularly gentle delivery method, the cells are able to survive post printing and can either be analyzed thereafter or grown into clonal colonies. To determine clonality, multiple images are recorded during the process. Cross-contamination is avoided by the use of disposable parts.